These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 4943397)
21. Lamprene: first results of treatment in the Netherlands in a group of 6 leprosy patients. Hogerzeil LM Dermatologica; 1971; 143(6):339-44. PubMed ID: 5150817 [No Abstract] [Full Text] [Related]
22. Editorial: Prevention of leprosy. J Trop Med Hyg; 1974 Mar; 77(3):49. PubMed ID: 4598138 [No Abstract] [Full Text] [Related]
25. [. 663 (G 30320 "Geigy"), a new chemotherapeutic agent against leprosy]. Vischer WA Schweiz Med Wochenschr; 1967 Mar; 97(10):308. PubMed ID: 5585384 [No Abstract] [Full Text] [Related]
26. The bases of chemotherapy and immunosuppressive therapy in leprosy. Browne SG Int J Lepr Other Mycobact Dis; 1971; 39(2):406-12. PubMed ID: 4948083 [No Abstract] [Full Text] [Related]
27. [Current state of thalidomide treatment of leprosy and leprosy reaction]. Sheskin J; Sagher F Arch Klin Exp Dermatol; 1970; 237(1):312-6. PubMed ID: 4906813 [No Abstract] [Full Text] [Related]
28. The impact of experimental human leprosy in the mouse on leprosy research. Rees RJ Int J Lepr Other Mycobact Dis; 1971; 39(2):201-15. PubMed ID: 4948076 [No Abstract] [Full Text] [Related]
29. Controlled drug trial of B.663 compared with DDS. Preliminary (48 week) report. Tolentino JG; Rodriquez JN; Abalos RM Int J Lepr Other Mycobact Dis; 1971; 39(3):738-41. PubMed ID: 5169924 [No Abstract] [Full Text] [Related]
30. Primary dapsone-resistant leprosy in Cebu, Philippines. Guinto RS; Cellona RV; Fajardo TT; de la Cruz EC Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):427-30. PubMed ID: 7042607 [TBL] [Abstract][Full Text] [Related]
32. [Clinical and paraclinical aspects of secondary drug resistance to 4-4' diaminodiphenylsulfone in a population of leprosy patients in Bamako, Republic of Mali]. Baquillon G; Ferracci C; Diallo J; Saint-Andreé P; Pattyn SR Acta Leprol; 1981; 85():40-52. PubMed ID: 6805234 [No Abstract] [Full Text] [Related]
33. Clofazimine in leprosy. Browne SG Br Med J; 1972 Feb; 1(5798):506-7. PubMed ID: 4550304 [No Abstract] [Full Text] [Related]
34. Efficacy of clofazimine in the prophylaxis and suppression of reactive phases of lepromatous leprosy. Karat AB; Jeevaratnam A; Karat S; Rao PS Int J Lepr Other Mycobact Dis; 1971; 39(4):838-41. PubMed ID: 5170472 [No Abstract] [Full Text] [Related]
35. [Prevalence of dapsone-resistant leprosy in Burundi. Temporary results]. Bourland J; Van Loo L; Pattyn SR Acta Leprol; 1982; (86-87):29-33. PubMed ID: 6815995 [No Abstract] [Full Text] [Related]
36. [Current treatment of leprosy in the Malta pavilion of the Hôpital Saint-Louis]. Pennec J Ann Med Interne (Paris); 1974; 125(6-7):561-4. PubMed ID: 4440971 [No Abstract] [Full Text] [Related]
37. Leprosy reactional states and their treatment. Jolliffe DS Br J Dermatol; 1977 Sep; 97(3):345-52. PubMed ID: 336075 [No Abstract] [Full Text] [Related]
38. Chemotherapy of leprosy. Leiker DL Int J Lepr Other Mycobact Dis; 1971; 39(2):462-6. PubMed ID: 4948084 [No Abstract] [Full Text] [Related]
39. [Incorporation of thalidomide to the therapeutic arsenal of Hansen's disease (award of the Spanish Academy of Dermatology 1968)]. Sheskin J Actas Dermosifiliogr; 1969; 60(3):57-72. PubMed ID: 5800285 [No Abstract] [Full Text] [Related]